VistaGen Therapeutics, Inc.
NASDAQ:VTGN
3.48 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | VistaGen Therapeutics, Inc. | 
| Symbool | VTGN | 
| Munteenheid | USD | 
| Prijs | 3.48 | 
| Beurswaarde    |  106,768,140 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 1.9 - 3.88 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. Shawn K. Singh J.D. | 
| Website | https://www.vistagen.com | 
An error occurred while fetching data.
Over VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









